Financial News

Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,421.49 +47.79 (+3.48%)

Delayed Quote Updated: 1:28 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Can GLP-1s Fatten Your Portfolio? We Examine the VanEck Pharmaceutical ETF vs State Street SPDR Pharmaceuticals ETF ↗

Today 10:29 EDT

VanEck's concentrated 26-stock portfolio delivered stronger five-year returns and lower volatility, while State Street's 62-holding fund offers broader diversification and lower fees.

Via The Motley Fool

Topics ETFs

Novo Has Big Plans for 2030. Should You Buy the Stock Now? ↗

October 29, 2026

The company’s comeback strategy looks sound.

Via The Motley Fool

Eli Lilly (LLY) Q3 2026 Earnings Call Transcript ↗

October 29, 2026

Revenue surged 39% on blockbuster obesity drug demand and strong international growth.

Via The Motley Fool

Topics Earnings

Eli Lilly (NYSE:LLY) Beats Q3 Estimates, Raises Guidance as Shares Jump ↗

October 29, 2026

Via Chartmill

S&P 500 Top Movers: Oct. 29, 2026 Gainers and Losers ↗

October 29, 2026

Via Chartmill

Topics Stocks

Eli Lilly Sells 53% More at Lower Prices: Rapid Earnings Reaction ↗

October 29, 2026

Eli Lilly’s realized prices fell 15%, but a 53% jump in volume pushed revenue up 39% and lifted full-year guidance by $5.5 billion. Here’s why the math works, and what could break it.

Via The Motley Fool

S&P 500 Top Movers: Today's US Session Gainers and Losers ↗

October 29, 2026

Via Chartmill

Topics Stocks

S&P 500 Gap Movers: October 29, 2026 Session ↗

October 29, 2026

Via Chartmill

Topics Stocks

Eli Lilly (LLY) shares skyrocket, what you need to know

October 29, 2026

What happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 8.1% in the morning session after the company reported third-quarter 2026 ...

Via StockStory

The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth

October 29, 2026

Breakthroughs in obesity, diabetes, oncology, and targeted therapies are driving fresh interest in peptide-based medicines and the companies developing the next generation of treatments.

From FN Media

Via GlobeNewswire

The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth

October 29, 2026

EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:NVO),(NYSE:HIMS),(NYSE:ENHA),(NYSE:LLY) EQNX::TICKER_END

Via FinancialNewsMedia

Eli Lilly Blows Past Sales Expectations And Hikes Outlook On Mounjaro, Zepbound Dominance ↗

October 29, 2026

Eli Lilly stock jumped early Thursday on a solid third-quarter report on the back of Mounjaro and Zepbound.

Via Investor's Business Daily

Eli Lilly (NYSE:LLY) reports upbeat Q3 2026, guides for strong full-year sales

October 29, 2026

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q3 2026 results beating Wall Street’s revenue expectations, with revenue up 38.6% year on year to...

Via StockStory

Could Revolution Medicines Be a Millionaire-Maker Stock? ↗

October 29, 2026

The path for Revolution Medicines to grow an initial investment of $25,000 into $1 million is a daunting one.

Via The Motley Fool

Eli Lilly's Next-Gen Obesity Drug Trounces Ozempic In Head-To-Head Test ↗

October 28, 2026

Eli Lilly's next-generation weight-loss drug, retatrutide, trounced Novo's Ozempic in a head-to-head study.

Via Investor's Business Daily

Eli Lilly (LLY) reports earnings tomorrow: what to expect

October 27, 2026

Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting earnings this Thursday before market hours. Here’s what you need to know. Eli Lilly beat...

Via StockStory

Topics Artificial Intelligence

$10,000 Invested in Eli Lilly 5 Years Ago Would Be Worth This Much Today ↗

October 27, 2026

The company has made longtime shareholders much richer.

Via The Motley Fool

Topics ETFs

Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts ↗

October 26, 2026

MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment.

Via MarketBeat

Topics Artificial Intelligence

Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH? ↗

October 26, 2026

IHE has outperformed recently by concentrating in U.S. drugmakers. PPH offers global reach and a higher dividend for investors willing to trade some of that momentum for income.

Via The Motley Fool

Topics ETFs

Which Healthcare ETF Is the Better Buy: Fidelity’s FHLC or State Street’s XLV? ↗

October 26, 2026

XLV concentrates on 61 large-cap S&P 500 names, while FHLC casts a wider net with 365 holdings across mid and small caps. Both charge 0.08% annually.

Via The Motley Fool

Topics ETFs Stocks

Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings? ↗

October 25, 2026

Bristol Myers Squibb is facing a sizable patent cliff, but that's not unusual in the pharma sector.

Via The Motley Fool

Topics Intellectual Property

The Nasdaq Just Had Its Worst Day in 4 Months. Here's the Level That Would Signal a Correction, and What History Says Investors Can Do About It. ↗

October 24, 2026

Tech stocks are selling off as investors question the payoff of artificial intelligence (AI) infrastructure spending.

Via The Motley Fool

Topics Artificial Intelligence Stocks

2 Growth Stocks to Hold for the Next Decade (Hint: These Aren’t AI Stocks) ↗

October 23, 2026

These drugmakers are capitalizing on their pipeline successes.

Via The Motley Fool

Topics Artificial Intelligence

Eli Lilly's Fast Growth Hasn't Slowed Its Progress As Sustainability Leader ↗

October 23, 2026

Eli Lilly's commitment to philanthropy, coupled with a dedication to environmental progress, make it a sustainability leader.

Via Investor's Business Daily

Topics Artificial Intelligence

3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach ↗

October 23, 2026

Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.

Via MarketBeat

The S&P 500 May Depend on the Fortunes of These 3 Companies Right Now. Here’s the Good News and the Bad News for Investors. ↗

October 23, 2026

These companies make up about 20% of the index.

Via The Motley Fool

Topics Economy Stocks

Q2 earnings highs and lows: Eli Lilly (NYSE:LLY) vs the rest of the branded pharmaceuticals stocks

October 22, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026? ↗

October 22, 2026

Amgen trades at half the valuation multiple of Eli Lilly while generating stronger free cash flow, but explosive growth in obesity drugs tells a different story.

Via The Motley Fool

Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results? ↗

October 22, 2026

Eli Lilly's revenue nearly doubled over two years while Bristol Myers Squibb remained relatively flat, widening the gap between these two pharma giants.

Via The Motley Fool

Topics Artificial Intelligence Lawsuit

Vanguard Health Care ETF vs iShares U.S. Healthcare ETF ↗

October 21, 2026

VHT's 411 holdings and 0.09% expense ratio deliver identical 5-year returns to IYH's concentrated 100-stock portfolio, raising questions about whether lower costs justify broader diversification.

Via The Motley Fool

Topics ETFs

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Financial News

Eli Lilly (NY:LLY)

All News about Eli Lilly

Popular Pages